Longeveron Inc (LGVN)

$0.54 -0.02 (-4.23%)
Market Cap 11.94M
Revenue (ttm) 2.39M
Net Income (ttm) -15.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -668.20%
Debt to Equity Ratio 0.00
Volume 246,100
Avg Vol 338,972
Day's Range N/A - N/A
Shares Out 21.33M
Stochastic %K 12%
Beta 0.21
Analysts Strong Sell
Price Target $6.86

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
Dorps332
Dorps332 Jan. 29 at 9:24 PM
$TCGL come take on $LGVN float is about the exact same
1 · Reply
Lstreak
Lstreak Jan. 29 at 3:32 PM
$LGVN They will need a capitol raise soon (dilution) and being under a dollar will bring it down much further. Even all things perfect if any product is approved they will still require funds for commercialization.
1 · Reply
Dorps332
Dorps332 Jan. 29 at 3:09 PM
$LGVN worst investment ever
0 · Reply
Svitlana
Svitlana Jan. 29 at 2:57 PM
$LGVN ✍️ 2k
0 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 29 at 2:19 PM
$LGVN Longeveron Receives Patent From Japan Patent Office Covering Potency Assay Methods For Assessing Human Mesenchymal Stem Cells
1 · Reply
ArlendMcfarland
ArlendMcfarland Jan. 26 at 4:19 PM
$LGVN +10000%
0 · Reply
Dorps332
Dorps332 Jan. 26 at 2:34 PM
$LGVN 😂 nothing can help this thing get over $1
1 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 26 at 2:19 PM
$LGVN Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire January 26, 2026 - ELPIS II top-line trial results are anticipated in the third quarter of 2026 - Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positive - U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation - Laromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunities
0 · Reply
winners234
winners234 Jan. 26 at 2:18 PM
$LGVN
0 · Reply
volatilelt
volatilelt Jan. 26 at 5:39 AM
$LGVN Any ideas will it run to 1$ to be compliant or another reverse split is coming? Couple of months left to comply, something should happen soon enough
1 · Reply
Latest News on LGVN
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Jan 29, 2026, 9:15 AM EST - 5 days ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 29, 2025, 9:15 AM EST - 5 weeks ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 2 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 2 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 2 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 2 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:36 PM EST - 3 months ago

Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 3 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 4 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 5 months ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 5 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 10:55 PM EDT - 6 months ago

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 6 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 6 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 6 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 6 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 7 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 7 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 7 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 8 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 8 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 9 months ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 9 months ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

May 9, 2025, 5:31 PM EDT - 9 months ago

Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 9 months ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 9 months ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 11 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 11 months ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 7:04 PM EST - 1 year ago

Longeveron Inc. (LGVN) Q4 2024 Earnings Call Transcript

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:37 PM EST - 1 year ago

Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:58 PM EDT - 1 year ago

Longeveron, Inc. (LGVN) Q2 2024 Earnings Call Transcript

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 18, 2024, 8:45 AM EDT - 1 year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Longeveron stock opened 100% up on Wednesday: explore why

Jul 10, 2024, 11:38 AM EDT - 1 year ago

Longeveron stock opened 100% up on Wednesday: explore why

Dorps332
Dorps332 Jan. 29 at 9:24 PM
$TCGL come take on $LGVN float is about the exact same
1 · Reply
Lstreak
Lstreak Jan. 29 at 3:32 PM
$LGVN They will need a capitol raise soon (dilution) and being under a dollar will bring it down much further. Even all things perfect if any product is approved they will still require funds for commercialization.
1 · Reply
Dorps332
Dorps332 Jan. 29 at 3:09 PM
$LGVN worst investment ever
0 · Reply
Svitlana
Svitlana Jan. 29 at 2:57 PM
$LGVN ✍️ 2k
0 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 29 at 2:19 PM
$LGVN Longeveron Receives Patent From Japan Patent Office Covering Potency Assay Methods For Assessing Human Mesenchymal Stem Cells
1 · Reply
ArlendMcfarland
ArlendMcfarland Jan. 26 at 4:19 PM
$LGVN +10000%
0 · Reply
Dorps332
Dorps332 Jan. 26 at 2:34 PM
$LGVN 😂 nothing can help this thing get over $1
1 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 26 at 2:19 PM
$LGVN Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) GlobeNewswire January 26, 2026 - ELPIS II top-line trial results are anticipated in the third quarter of 2026 - Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positive - U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation - Laromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunities
0 · Reply
winners234
winners234 Jan. 26 at 2:18 PM
$LGVN
0 · Reply
volatilelt
volatilelt Jan. 26 at 5:39 AM
$LGVN Any ideas will it run to 1$ to be compliant or another reverse split is coming? Couple of months left to comply, something should happen soon enough
1 · Reply
GreenSale
GreenSale Jan. 24 at 7:17 AM
$LGVN $MAIA time for LGVN to catch up
0 · Reply
Kingdaley
Kingdaley Jan. 23 at 8:08 PM
$LGVN It’s about to make a run for sure
0 · Reply
poilu
poilu Jan. 23 at 7:47 PM
$LGVN Up almost 5%....did someone accidentally buy shares here?
0 · Reply
GreenSale
GreenSale Jan. 21 at 3:13 AM
$LGVN
0 · Reply
GreenSale
GreenSale Jan. 21 at 3:13 AM
$LGVN seems like a solid entry to me
0 · Reply
HoldingontoPennies
HoldingontoPennies Jan. 20 at 4:59 PM
$LGVN seems everyone is red here… hold this one. Any volume over 2 million gonna rocket this. One of those bios you hold and wake up to 200% news. Good luck everyone💪
0 · Reply
FeedMeWealth
FeedMeWealth Jan. 16 at 7:15 PM
$MAIA this and $LGVN my two favorite BioTech
1 · Reply
BigTimePennyStocks
BigTimePennyStocks Jan. 12 at 1:28 AM
Small-Cap with Catalysts this week: 👇👇 ( $AUUD, $XRTX, $OFAL, $LGVN, $ENVB, etc...) #NASDAQ #NYSE
0 · Reply
janlukas
janlukas Jan. 9 at 8:43 AM
$LGVN Regarding Lgvn I heard Gates Venture associated. The last time Bill Gates was interested in a company, see Novavax, it went from 0.50 cents to $370 in 1 year.
1 · Reply
ACInvestorBlog
ACInvestorBlog Jan. 7 at 8:26 PM
$LGVN beaten down small Alzheimer name on watch.
1 · Reply
Banelamhh
Banelamhh Jan. 6 at 4:50 AM
$LGVN make a move
0 · Reply
GioWave
GioWave Jan. 2 at 8:41 PM
$LGVN to be acquired by Big European Pharma before 2026 year-end. More stock price weakness/dilution coming in the next weeks/months before completing the transaction.
1 · Reply